

1 8. The method according to claim 7, wherein the compound inhibiting the function
2 of MK is an antisense oligonucleotide that inhibits intracellular MK protein synthesis by
3 binding to a segment of a single-stranded mRNA transcribed from the MK gene.

A1
1 9. The method according to claim 7, wherein the compound inhibiting the function
2 of MK is an antibody against the MK protein or a fragment comprising its variable region.

1 10. The method according to claim 7, wherein said angiostenosis is caused by
2 arteriosclerosis or restenosis after PTCA surgery.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or
1.17 as required by this paper to Deposit Account 19-0065.

Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Address : 2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

DRS/la

Attachments: Paper copy of new Sequence Listing pages 1-6

09763536 044294
T 0362449 99569460